Default company panoramic image

Actinobac Biomed, Inc.

Therapeutics for the treament of hematological malignancies, autoimmune diseases, and latent HIV infection.

  • Stage Product In Development
  • Industry Biotechnology
  • Location North Brunswick, NJ, USA
  • Currency USD
  • Founded September 2009
  • Employees 1
  • Website

Company Summary

Actinobac Biomed, Inc. is a New Jersey-based start-up company engaged in the development of proprietary biopharmaceuticals with multiple potential indications, including several with major medical impact/importance and market size, including hematological malignancies, autoimmune/inflammatory diseases, and HIV infection. The company has developed a product, called Leukothera™ (LtxA), a protein produced by a strain of bacteria that occupies the o


  • Default avatar
    Benjamin Andrew Belinka Jr.
    CEO / President

    After obtaining his Ph.D. in Chemistry, Dr. Belinka joined Sandoz, Inc. supervising a R&D laboratory for seven years. He then joined Cytogen, Inc. where, as Director of Preclinical Research, he acted with the other member of project teams to bring three cancer diagnostics and a bone pain agent to market. Since 1999, he has worked with a number of start-up pharmaceutical and biotechnology companies as a consultant or senior executive.

  • Default avatar
    Scott Charles Kachlany
    CSO / Founder

    Dr. Kachlany received a Ph.D. at Columbia University and then joined the Oral Biology Department at UMDNJ Dental School. His work on bacteria isolated in the human mouth led him to identify and explore the pharmaceutical utility of the protein drug candidate, Leukothera. In 2009, he founded Actinobac Biomed, Inc. to commercialize therapeutic agents for the treatment of diseases which have or will afflict over 40% of the world's population.

Previous Investors

  • Default avatar
    Foundation Venture Capital Group, Inc.